Recent

% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

r1t2003 10 posts  |  Last Activity: Jan 11, 2016 6:10 AM Member since: Dec 9, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • r1t2003 by r1t2003 Jan 11, 2016 6:10 AM Flag

    Qsymia (VVUS)
    IMS:
    •NRx: up 3.5% (5,348 vs. 5,166; now 29.8% of the 4-drug total vs. 29.7% last week)
    •TRx: up 6.1% (8,591 vs. 8,098; now 27.5% of the 4-drug total vs. 28.0% last week)

    Symphony Health:
    •NRx: up 2.4% (4,665 vs. 4,554; now 23.1% of the 4-drug total vs. 23.0% last week)
    •TRx: up 5.1% (7,114 vs. 6,771; now 21.2% of the 4-drug total vs. 21.6% last week)

    Contrave (OREX)
    IMS:
    •NRx: up 2.7% (6,878 vs. 6,700; now 38.3% of the 4-drug total vs. 38.5% last week)
    •TRx: up 8.1% (12,205 vs. 11,289; now 39.0% of the 4-drug total vs. 39.1% last week)
    Symphony Health:
    •NRx: up 1.3% (8,244 vs. 8,139; now 40.8% of the 4-drug total vs. 41.1% last week)
    •TRx: up 5.7% (13,967 vs. 13,212; now 41.6% of the 4-drug total vs. 42.2% last week)

    BELVIQ (ARNA)
    IMS:
    •NRx: up 5.3% (4,622 vs. 4,390; now 25.7% of the 4-drug total vs. 25.2% last week)
    •TRx: up 10.8% (8,159 vs. 7,366; now 26.1% of the 4-drug total vs. 25.5% last week)

    Symphony Health:
    •NRx: up 4.5% (5,585 vs. 5,347; now 27.6% of the 4-drug total vs. 27.0% last week)
    •TRx: up 10.6% (9,376 vs. 8,474; now 28.0% of the 4-drug total vs. 27.1% last week)

  • r1t2003 by r1t2003 Dec 12, 2015 2:44 AM Flag

    Qsymia (VVUS)
    Qsymia TRx were up 21.1% and 23.0% according to IMS and SH, respectively, with its market share at 21-27%. Qsymia TRx is now increasing at an average of 0.4% per week over the last 5 weeks according to IMS data.

    IMS:
    •NRx: up 22.2% (6,836 vs. 5,594; now 28.4% of the 4-drug total vs. 29.7% last week)
    •TRx: up 21.1% (10,386 vs. 8,573; now 27.1% of the 4-drug total vs. 28.1% last week)

    Symphony Health:
    •NRx: up 25.4% (6,168 vs. 4,919; now 22.3% of the 4-drug total vs. 23.0% last week)
    •TRx: up 23.0% (8,866 vs. 7,207; now 21.1% of the 4-drug total vs. 21.8% l
    Contrave (OREX)

    Contrave continues to lead the branded obesity market, backed by 900-person Takeda salesforce. Contrave TRx were up 26.7% and 27.5% according to IMS and SH, respectively, and the drug now has a ~39-42% TRx market share. Contrave TRx is now increasing at an average of 1.6% per week over the last 5 weeks according to IMS data.

    IMS:
    •NRx: up 29.5% (9,352 vs. 7,219; now 38.8% of the 4-drug total vs. 38.3% last week)
    •TRx: up 26.7% (14,996 vs. 11,840; now 39.1% of the 4-drug total vs. 38.7% last week)

    Symphony Health:
    •NRx: up 29.8% (11,350 vs. 8,741; now 41.0% of the 4-drug total vs. 40.9% last week)
    •TRx: up 27.5% (17,469 vs. 13,704; now 41.6% of the 4-drug total vs. 41.5% last week)

    BELVIQ (ARNA)

    BELVIQ has 27.1% and 29.0% of the TRx, according to IMS and SH, respectively. BELVIQ TRx had increases of 27.8% and 29.2% this week, to 10,397 and 12,173 TRx, according to IMS and SH, respectively. BELVIQ TRx is now increasing at an average of 0.9% per week over the last 5 weeks according to IMS data.

    IMS:
    •NRx: up 30.1% (6,424 vs. 4,939; now 26.7% of the 4-drug total vs. 26.2% last week)
    •TRx: up 27.8% (10,397 vs. 8,134 ; now 27.1% of the 4-drug total vs. 26.6% last week)

    Symphony Health:
    •NRx: up 30.8% (7,903 vs. 6,041; now 28.6% of the 4-drug total vs. 28.2% last week)
    •TRx: up 29.2% (12,173 vs. 9,422; now 29.0% of the 4-drug total vs. 28.5% last week)

  • r1t2003 by r1t2003 Nov 30, 2015 7:31 AM Flag

    Qsymia (VVUS)
    IMS
    •NRx: up 1.3% (7,110 vs. 7,022; now 28.6% of the 4-drug total vs. 28.8% last week)
    •TRx: up 2.1% (10,565 vs. 10,343; now 27.7% of the 4-drug total vs. 27.6% last week)

    Symphony Health:
    •NRx: up 0.5% (6,319 vs. 6,287; now 22.3% of the 4-drug total vs. 22.3% last week)
    •TRx: up 1.0% (8,958 vs. 8,868; now 21.5% of the 4-drug total vs. 21.5% last week)

    Contrave (OREX)
    IMS:
    NRx: up 4.6% (9,828 vs. 9,398; now 39.6% of the 4-drug total vs. 38.5% last week)
    TRx: up 3.4% (14,965 vs. 14,471; now 39.2% of the 4-drug total vs. 38.6% last week)

    Symphony Health:
    NRx: up 2.8% (11,834 vs. 11,516; now 41.8% of the 4-drug total vs. 40.9% last week)
    TRx: up 2.7% (17,464 vs. 16,997; now 41.9% of the 4-drug total vs. 41.2% last week)

    BELVIQ (ARNA)
    IMS:
    NRx: down 1.1% (6,510 vs. 6,584; now 26.2% of the 4-drug total vs. 27.0% last week)
    TRx: down 1.8% (10,194 vs. 10,376 ; now 26.7% of the 4-drug total vs. 27.6% last week)

    Symphony Health:
    NRx: down 3.1% (7,948 vs. 8,200; now 28.1% of the 4-drug total vs. 29.1% last week)
    TRx: down 2.2% (11,958 vs. 12,221; now 28.7% of the 4-drug total vs. 29.6% last week)

  • r1t2003 by r1t2003 Nov 14, 2015 4:12 AM Flag

    Qsymia (VVUS)
    IMS:
    •NRx: up 0.4% (7,143 vs. 7,116; now 28.6% of the 4-drug total vs. 28.7% last week)
    •TRx: down 0.7% (10,543 vs. 10,620; now 27.4% of the 4-drug total vs. 27.9% last week)

    Symphony Health:
    •NRx: up 1.3% (6,486 vs. 6,401; now 22.6% of the 4-drug total vs. 22.7% last week)
    •TRx: up 0.9% (9,126 vs. 9,044; now 21.6% of the 4-drug total vs. 21.8% last week)

    BELVIQ (ARNA)
    IMS:
    •NRx: up 1.4% (6,794 vs. 6,700; now 27.2% of the 4-drug total vs. 27.0% last week)
    •TRx: up 2.6% (10,803 vs. 10,534; now 28.1% of the 4-drug total vs. 27.7% last week)

    Symphony Health:
    •NRx: up 2.2% (8,415 vs. 8,231; now 29.3% of the 4-drug total vs. 29.2% last week)
    •TRx: up 2.6% (12,719 vs. 12,399; now 30.0% of the 4-drug total vs. 29.8% last week)

    CONTRAVE (OREX)
    IMS:
    •NRx: down 0.3% (9,622 vs. 9,648; now 38.6% of the 4-drug total vs. 38.9% last week)
    •TRx: up 1.2% (14,800 vs. 14,622; now 38.5% of the 4-drug total vs. 38.4% last week)

    Symphony Health:
    •NRx: up 0.8% (11,711 vs. 11,618; now 40.8% of the 4-drug total vs. 41.2% last week)
    •TRx: up 1.8% (17,371 vs. 17,063; now 41.0% of the 4-drug total vs. 41.1% last week)

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 4:01 PM Flag

    bubbles.......... without a doubt you are an idiot.
    STENDRA approved APRIL 27, 2012.
    Product licensed to Auxillium OCt. 11, 2013
    That's 17.5 months.
    You can count the months using your fingers and toes.

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 3:42 PM Flag

    vinthebot..........,
    A deal is not a deal until you sign on the dotted line and it wasn't signed until 18 months after STENDRA was approved.

    Here the facts: CHESTERBROOK, Pa., Oct. 11, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. The parties also simultaneously signed a Commercial Supply Agreement pursuant to which VIVUS will ..................

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 3:21 PM Flag

    BUBBLES SAID.....Stendra wasnt even approved yet when VVUS landed AUXL as its partner and certainly the 15 minutes label change was not approved as well when AUXL became their partner.

    Apparently your short term memory is failing.
    18 months is a long time to wait to announce a formal agreement after STENDRA was approved.
    You can double talk all you want but it's obvious you hadn't done your DD like the infamous pmt111.

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 3:05 PM Flag

    . but even if it took 18 months to ink a partner which AXUL may have been on board way before 18 months but the details were not finalized until October.

    Fact is STENDRA didn't have a marketing partner for 18 months after approval yet you claimed otherwise. Admit you were 100% wrong and even pmt111 will forgive you.

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 2:31 PM Flag

    bubbles......You apparently know little about the life of STENDRA.
    1. .......... STENDRA was approved on APRIL 27, 2012 .
    2............. STENDRA was licensed to Auxillium on OCT 11, 2013. That was 18 months after the initial approval.
    3..............STENDRA received the 15 minute label SEPT. 18, 2014 . That was 11 months after Auxillium signed their initial licensing agreement.

  • Reply to

    Very low volume right now

    by josephanastasiw Nov 11, 2015 10:45 AM
    r1t2003 r1t2003 Nov 11, 2015 1:41 PM Flag

    bubbles... It took VVUS over a year to find a marketing partner (Auxilium) for Stendra. Now what makes you think they will have an easier time of it a second time around if ENDO decides to sell/return Stendra marketing rights to VVUS.

VVUS
0.9498+0.0298(+3.24%)9:35 AMEST